BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9087486)

  • 1. Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.
    Visalli MA; Jacobs MR; Moore TD; Renzi FA; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):767-70. PubMed ID: 9087486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
    Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
    López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
    Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides.
    Joly-Guillou ML; Decré D; Herrman JL; Bourdelier E; Bergogne-Bérézin E
    J Antimicrob Chemother; 1995 Oct; 36(4):619-29. PubMed ID: 8591936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species.
    Suh B; Shapiro T; Jones R; Satishchandran V; Truant AL
    Diagn Microbiol Infect Dis; 1995 Feb; 21(2):111-4. PubMed ID: 7628190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.
    Pankuch GA; Jacobs MR; Rittenhouse SF; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2317-22. PubMed ID: 7840563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.
    Muñoz Bellido JL; Muñoz Criado S; García García I; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; García-Rodríguez JA
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2612-5. PubMed ID: 9420028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of clinical isolates of Acinetobacter baumannii.
    Shi ZY; Liu PY; Lau Y; Lin Y; Hu BS; Shir J-M
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):81-5. PubMed ID: 9147913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
    Ling TK; Ying CM; Lee CC; Liu ZK
    Med Princ Pract; 2005; 14(5):338-41. PubMed ID: 16103700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1546-50. PubMed ID: 2221864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and changing minimum inhibitory concentration (MIC) of Acinetobacter species from a tertiary care setup.
    Capoor MR; Nair D; Srivastava L; Gupta B; Aggarwal P
    J Commun Dis; 2005 Jun; 37(2):99-107. PubMed ID: 16749272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of seven new beta-lactams, alone and in combination with beta-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins.
    Gupta V; Datta P; Agnihotri N; Chander J
    Braz J Infect Dis; 2006 Feb; 10(1):22-5. PubMed ID: 16767311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.
    Brauers J; Frank U; Kresken M; Rodloff AC; Seifert H
    Clin Microbiol Infect; 2005 Jan; 11(1):24-30. PubMed ID: 15649300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.
    Wolff M; Joly-Guillou ML; Farinotti R; Carbon C
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1406-11. PubMed ID: 10348761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
    Jacobs MR; Spangler SK; Appelbaum PC
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.